Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab versus investigator's choice standard chemotherapy in relapsed or refractory classical Hodgkin lymphoma
CTR20211254Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of penpulimab in classical Hodgkin lymphoma (cHL), sponsored by Akeso, Inc.. Started Mar 2022; status: active.
02
Drugs
penpulimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on CTR20211254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211254.